AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) delivered a powerful year-end surge, posting preliminary fourth-quarter sales of about $823.2 million and capping 2025 with roughly $2.936 billion in revenue, a performance that positions the spine-technology company for another aggressive growth run in 2026.
The fourth-quarter figure represents a 25.2 percent jump from a year earlier, while full-year sales climbed 16.5 percent, reflecting strong demand across Globus’s core businesses and the impact of its recent acquisitions. Management said momentum built steadily through the year as the company expanded market share in its U.S. Spine franchise and posted record results in its Enabling Technologies unit.
President and Chief Executive Officer Keith Pfeil said the company closed 2025 with strong operational and commercial traction, pointing to continued gains in spine procedures and rapid progress integrating the Nevro acquisition alongside NuVasive. He said the company is heading into 2026 with confidence, backed by a deep product pipeline, disciplined investment strategy, and a focus on sustained, profitable growth.
Chief Financial Officer Kyle Kline said the underlying business remained healthy even when stripping out the newly acquired Nevro unit. Excluding Nevro, Globus’s base business generated $723.3 million in fourth-quarter revenue, up 10.0 percent from the prior year, led by continued strength in U.S. Spine.
That core growth, combined with contributions from acquired businesses, has allowed Globus to set an ambitious outlook for the coming year. The company forecast full-year 2026 revenue between $3.18 billion and $3.22 billion and projected fully diluted non-GAAP earnings per share in a range of $4.30 to $4.40, signaling management’s expectation that scale and operating leverage will continue to build.
The results released Thursday are preliminary and unaudited, based on management’s initial review of operations for the quarter and full year ended December 31, 2025, and could change when final numbers are reported. Globus said it plans to release its official fourth-quarter and full-year financial statements on February 24, 2026, after the market closes.
For investors, the numbers offer a clear message: Globus Medical is emerging from a year of heavy integration with accelerating revenue, expanding margins and a sharper competitive position in a fast-evolving medical technology market. With a multibillion-dollar revenue base now firmly in place, the company enters 2026 not as a consolidator finding its footing, but as a scaled-up player aiming to press its advantage.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.